EXPRESSION OF MIRNA-27A IN THE SERUM OF PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROME WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION
Coronary artery disease (CAD) is a multifactorial disorder. Previously have been identified genes whose polymorphic variants are associated with an increased risk of CAD. Genetic control of the development of CAD at the post-transcriptional level is carried out using step-wise and multicomponent regulation of gene expression with the participation of specific molecules called micro-ribonucleic acids (miRNAs). Currently, many authors consider these molecules, in particular miRNA-27a, as potential sensitive diagnostic markers for acute coronary syndrome (ACS). Aim. To assess the level of miRNA-27a expression in the serum of patients underwent percutaneous coronary intervention (PCI) after non-ST elevation ACS. Material and methods. Forty patients with non-ST elevation ACS who underwent coronary artery stenting were examined. The comparison groups consisted of 80 patients with a stable CAD who underwent coronary artery bypass surgery, and 20 patients without clinical signs of CAD operated due to valvular disorders without atherosclerotic lesions. All patients underwent coronary angiography. The expression level of miRNA-27a was determined in serum by real-time polymerase chain reaction. Results. In patients with non-ST elevation ACS, who underwent PCI, the expression level of miRNA-27a in serum was higher than in patients without atherosclerotic lesions (6,99±1,69 and 3,05±0,89, respectively; p<0,05). Moreover, patients with multivessel coronary lesions (3 or more arteries) had a higher level of miRNA-27a expression in serum than patients with a single or dual vascular lesion (8,00±2,19 and 5,87±2,64, respectively; p<0,05). In patients with non-ST elevation ACS and patients with a stable CAD, the expression level of miRNA-27a was not significantly different (6,99±1,69 and 8,57±3,90, respectively; p>0,05). Conclusion. High levels of miRNA-27a expression can be considered as a marker of coronary lesion severity in patients with CAD, but not as a marker for ACS.